Centre Oscar Lambret
- Address
- 3 Rue Frederic Combemale, 59000 Lille, France
Centre Oscar Lambret - Oncology Research Center
Centre Oscar Lambret is a specialized cancer research institution with expertise in advanced oncological therapeutics and multimodal treatment approaches. The center demonstrates particular strength in genitourinary oncology, focusing on innovative treatment strategies for complex malignancies.
- Prostate cancer with metastatic disease, particularly pelvic lymph node involvement
- Combined modality therapy integrating hormonal agents, radiation therapy, and androgen deprivation
- Novel androgen receptor inhibitors in hormone-naïve prostate cancer
The center's research portfolio emphasizes precision oncology approaches in locally advanced and metastatic prostate cancer, evaluating cutting-edge therapeutic combinations that integrate systemic treatments with radiotherapy. Their focus on failure-free survival outcomes reflects a commitment to improving long-term disease control and quality of life for patients with complex urological malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 19 therapeutic areas and 15 of 316 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 308 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Oscar Lambret
lock Showing 1 of 284 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| "TUC-TOC": Tucatinib in combination with Oral Etoposide (VP16) - Trastuzumab in Patients with metastatic HER2+ Breast cancer after progression under Tucatinib-Capecitabine-Trastuzumab or toxicity related to capecitabine: a multicenter Phase II | Institut Curie | Phase II | Recruiting | Dec 2023 | — |
IMP list
lock Showing 1 of 316 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 37 | Unknown | 2011-04-26 | 2026-06-15 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.